Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging.

Literature DB >> 25012872

Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging.

Laura Gilardi¹, Chiara Maria Grana, Giovanni Paganelli.

Abstract

Mesh：

Year: 2014 PMID： 25012872 DOI： 10.1007/s00259-014-2848-x

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

30 in total

1. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Authors: Wouter V Vogel; Aurelie Guislain; Pia Kvistborg; Ton N M Schumacher; John B A G Haanen; Christian U Blank
Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544

2. Reversal of the TCR stop signal by CTLA-4.

Authors: Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal: Science Date: 2006-08-24 Impact factor: 47.728

3. Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [¹⁰F]ICF01006, a highly promising melanoma PET tracer.

Authors: Latifa Rbah-Vidal; Aurélien Vidal; Sophie Besse; Florent Cachin; Mathilde Bonnet; Laurent Audin; Serge Askienazy; Frédéric Dollé; Françoise Degoul; Elisabeth Miot-Noirault; Nicole Moins; Philippe Auzeloux; Jean-Michel Chezal
Journal: Eur J Nucl Med Mol Imaging Date: 2012-06-16 Impact factor: 9.236

4. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

Authors: Yulia Bronstein; Chaan S Ng; Patrick Hwu; Wen-Jen Hwu
Journal: AJR Am J Roentgenol Date: 2011-12 Impact factor: 3.959

5. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal: Clin Cancer Res Date: 2007-11-02 Impact factor: 12.531

6. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531

7. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Authors: Jeffrey S Weber; Reinhard Dummer; Veerle de Pril; Celeste Lebbé; F Stephen Hodi
Journal: Cancer Date: 2013-02-07 Impact factor: 6.860

8. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.

Authors: H Assi; K S Wilson
Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677

Review 9. Molecular probes for malignant melanoma imaging.

Authors: Gang Ren; Ying Pan; Zhen Cheng
Journal: Curr Pharm Biotechnol Date: 2010-09-01 Impact factor: 2.837

10. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Authors: M Reck; I Bondarenko; A Luft; P Serwatowski; F Barlesi; R Chacko; M Sebastian; H Lu; J-M Cuillerot; T J Lynch
Journal: Ann Oncol Date: 2012-08-02 Impact factor: 32.976

5 in total

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Authors: Narjess Ayati; Ramin Sadeghi; Zahra Kiamanesh; Sze Ting Lee; S Rasoul Zakavi; Andrew M Scott
Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-29 Impact factor: 9.236

2. The role of interim ¹⁸F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Authors: Christos Sachpekidis; Hoda Anwar; Julia Winkler; Annette Kopp-Schneider; Lionel Larribere; Uwe Haberkorn; Jessica C Hassel; Antonia Dimitrakopoulou-Strauss
Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-24 Impact factor: 9.236

Review 3. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Authors: Kristina Buder-Bakhaya; Jessica C Hassel
Journal: Front Immunol Date: 2018-06-28 Impact factor: 7.561

4. Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.

Authors: Aglaia Schiza; Sandra Irenaeus; Francisco Ortiz-Nieto; Angelica Loskog; Thomas Tötterman; Anders Sundin; Gustav J Ullenhag; Håkan Ahlström
Journal: Sci Rep Date: 2019-12-02 Impact factor: 4.379

Review 5. Thyroid cancer diagnosis in the era of precision imaging.

Authors: Kimberley-Jane Bonjoc; Hannah Young; Susanne Warner; Thomas Gernon; Ellie Maghami; Ammar Chaudhry
Journal: J Thorac Dis Date: 2020-09 Impact factor: 2.895

5 in total

Review 9. Molecular probes for malignant melanoma imaging.

Review 1. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Review 3. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Review 5. Thyroid cancer diagnosis in the era of precision imaging.

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.